Micrus' Cerecyte microcoil studies show good results

By Angela McDaniels

Seattle, Oct. 31 - Micrus Endovascular Corp. said its Cerecyte microcoils appear to improve intracranial aneurysm occlusion rates compared with bare platinum microcoils, according to two studies presented at the Eighth Congress of the World Federation of Interventional and Therapeutic Neuroradiology held in Venice, Italy.

In the first study, presented by Martin Bendszus of the University of Wurzburg, Germany, 18 of 26 patients treated for cerebral aneurysms with Cerecyte coils obtained complete aneurysm occlusion at the completion of the procedure. This number increased to 23 patients at six months following the procedure.

The second study, presented by Neil Gholkar of Newcastle, England, produced similar results in a population of 30 patients treated with Cerecyte microcoils.

Biotechnology company Micrus Endovascular develops implantable and disposable medical devices used in the treatment of cerebral vascular diseases and is based in Sunnyvale, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.